The Role of Medial Habenula-Interpeduncular Nucleus Pathway in Anxiety: A Dissertation
Authors
Pang, XueyanFaculty Advisor
Andrew R. Tapper, PhDAcademic Program
NeuroscienceDocument Type
Doctoral DissertationPublication Date
2015-06-22Keywords
Dissertations, UMMSAcetylcholine
Anxiety
Autoreceptors
Cholinergic Neurons
Habenula
Neurotransmitter Agents
Nicotine
Receptors, Nicotinic
Signal Transduction
Tobacco
Acetylcholine
Anxiety
Autoreceptors
Cholinergic Neurons
Habenula
Neurotransmitter Agents
Nicotine
Nicotinic Receptors
Signal Transduction
Tobacco
Behavioral Neurobiology
Molecular and Cellular Neuroscience
Metadata
Show full item recordAbstract
Recently, the medial habenula-interpeduncular (MHb-IPN) axis has been hypothesized to modulate anxiety although neuronal populations and molecular mechanisms regulating affective behaviors in this circuit are unknown. Here we show that MHb cholinergic neuron activity directly regulates anxiety-like behavior. Optogenetic silencing of MHb cholinergic IPN inputs reduced anxiety-like behavior in mice. MHb cholinergic neurons are unique in that they robustly express neuronal nicotinic acetylcholine receptors (nAChRs), although their role as autoreceptors in these neurons has not been described. nAChRs are ligand-gated cation channels that are activated by the excitatory neurotransmitter, acetylcholine (ACh), as well as nicotine, the addictive component of tobacco smoke. We expressed novel nAChR subunits that render nAChRs hypersensitive to ACh, ACh detectors, selectively in MHb cholinergic neurons of adult mice. Mice expressing these ACh detectors exhibited increased baseline anxiety-like behavior that was alleviated by blocking the mutant receptors. Under stressful conditions, such as during nicotine withdrawal, nAChRs were functionally upregulated in MHb cholinergic neurons mediating an increase in anxiety-like behavior. Together, these data indicate that MHb cholinergic neurons regulate anxiety via signaling through nicotinic autoreceptors and point toward nAChRs in MHb as molecular targets for novel anxiolytic therapeutics.DOI
10.13028/M2VP49Permanent Link to this Item
http://hdl.handle.net/20.500.14038/32181Rights
Copyright is held by the author, with all rights reserved.ae974a485f413a2113503eed53cd6c53
10.13028/M2VP49